Updated on 23 June 2014
Selecta will work with 3SBio to advance pegsiticase-based therapeutics as potential treatments for refractory and tophaceous gout as well as tumor lysis syndrome, with the ultimate goal of expeditiously moving toward regulatory approvals. Selecta and 3SBio have agreed to work together to achieve clinical proof of concept for SEL-212 and pegsiticase in human clinical trials in their territories; Selecta's territory includes US and all of Europe. Proof-of-concept clinical studies are expected to be initiated in 2015.
"Patients with refractory and tophaceous gout have currently very limited treatment options. Indeed, these patients generally cannot be successfully treated by conventional oral gout drugs," said Dr Jing Lou, CEO, 3SBio. "We are impressed with SVP's potential to greatly expand the safe and effective use of biological therapeutics. Our proven capabilities in manufacturing and development of biological therapeutics combined with Selecta's strong development capabilities and unique SVP platform, promise to be an effective partnership for expanding the use of pegsiticase. Together, we are committed to meeting the significant unmet needs of refractory and tophaceous gout patients."